Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- The GLP-1 Paradox in Colorectal Cancer (Medscape)
- The most pressing workforce issues for 103 healthcare leaders (Becker’s Healthcare)
- FDA-cleared GI test detects ‘most likely causes’ of diarrheal syndromes (Healio)
- A path forward: women in gastroenterology (Gastrointestinal Endoscopy)
- 5 Gastroenterology Headlines You Missed in February 2026 (HCP Live)
- Endoluminal Robotics – what it really is (How to Startup in MedTech)
- AI in GI: A Humanist Approach (GI & Endoscopy News)
- Gastroenterology and private equity in 2026: 5 notes (Becker’s GI & Endoscopy)
